

Balaglitazone

Catalog No: tcsc1441



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

199113-98-9

Formula:

$C_{20}H_{17}N_3O_4S$

Pathway:

Cell Cycle/DNA Damage

Target:

PPAR

Purity / Grade:

>98%

Solubility:

DMSO : \geq 500 mg/mL (1264.45 mM)

Alternative Names:

DRF 2593;NN 2344

Observed Molecular Weight:

395.43


Product Description

Balaglitazone is a selective partial **PPAR γ** agonist with an **EC₅₀** of 1.351 μ M for human **PPAR γ** .

IC50 & Target: EC50: 1.351 μ M (Human PPAR γ)^[1]

In Vitro: Balaglitazone is a selective partial PPAR γ agonist with an EC₅₀ of 1.351 μ M^[1]. Balaglitazone (5-100 μ M) has equal cytotoxicity towards K562 and K562/DOX cells. Balaglitazone decreases doxorubicin cytotoxicity in K562 and K562/DOX cells, with IC₅₀s of 0.117 μ M and 0.53 μ M, respectively. Balaglitazone reverses multidrug resistance (MDR) in K562/DOX cells. Balaglitazone (25 μ M) increases Rh123 accumulation in K562/DOX cells, but does not increase MFI in K562 cells. Balaglitazone downregulates P-gp expression in K562/DOX cells, and such effects are via upregulation of PTEN in K562/DOX cells, and be abolished by PTEN inhibition^[2].

In Vivo: Balaglitazone (3 mg/kg, p.o.) shows antihyperglycaemic activity in fully diabetic and insulin resistant db/db mice, and is more potent than the full PPAR γ agonist rosiglitazone^[1]. Balaglitazone (10 mg/kg, p.o.) suppresses overall glucose, decreases insulin levels, and increases bodyweight in male diet-induced obese rats, and such effects are equal to that of 30 mg/kg pioglitazone^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!